Скачать с ютуб ASCO GU 2022 - ERLEADA ® Real-World Study in Metastatic Castration-Sensitive Prostate Cancer or mCS в хорошем качестве

ASCO GU 2022 - ERLEADA ® Real-World Study in Metastatic Castration-Sensitive Prostate Cancer or mCS

Dr. Benjamin Lowentritt, MD, FACS, Director, Minimally Invasive Surgery and Robotics and Cancer Care Program at Chesapeake Urology and an investigator on the ERLEADA ® (apalutamide) real-world study discusses the findings ​that showed a more than 90 percent decline in ​prostate-specific antigen (​PSA​)​ at six months in a majority of patients with mCSPC, reinforcing the positive results found in the clinical trial setting. The patient-reported outcomes study demonstrated that rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer.​ These data were presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium​ 2022. #ERLEADA Dr. Lowentritt M.D., F.A.C.S. Director, Minimally Invasive Surgery and Robotics and Cancer Care Program, Chesapeake Urology​. ​Dr. Lowentritt has a general urology practice with a focus on minimally invasive techniques to treat urological conditions. His expertise includes robotic, laparoscopic, and endoscopic management of renal, bladder, and prostate cancer, as well as minimally invasive options for benign prostatic hyperplasia (BPH), kidney stones, pelvic organ prolapse, and ureteropelvic junction obstruction.